Edition:
United States

Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

133.69USD
12 Nov 2018
Change (% chg)

$-2.76 (-2.02%)
Prev Close
$136.45
Open
$136.32
Day's High
$136.32
Day's Low
$133.15
Volume
117,973
Avg. Vol
92,507
52-wk High
$138.69
52-wk Low
$96.70

Latest Key Developments (Source: Significant Developments)

Charles River Laboratories Q4 GAAP Loss Per Share $0.63
Tuesday, 13 Feb 2018 07:01am EST 

Feb 13 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS FROM CONTINUING OPERATIONS AND PROVIDES 2018 GUIDANCE.Q4 NON-GAAP EARNINGS PER SHARE $1.40.Q4 GAAP LOSS PER SHARE $0.63.Q4 REVENUE ROSE 2.5 PERCENT TO $478.5 MILLION.Q4 EARNINGS PER SHARE VIEW $1.25, REVENUE VIEW $474.6 MILLION -- THOMSON REUTERS I/B/E/S.CHARLES RIVER LABORATORIES SEES 2018 NON-GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS $5.42 - $5.57.CHARLES RIVER LABORATORIES SEES 2018 GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS $4.71 - $4.86.SEES 2018 REVENUE GROWTH, REPORTED, FROM CONTINUING OPERATIONS OF 7.2% TO 8.2%.FY2018 EARNINGS PER SHARE VIEW $5.58, REVENUE VIEW $1.99 BILLION -- THOMSON REUTERS I/B/E/S.CHARLES RIVER LABORATORIES - EXCLUDING MPI, 2018 EPS EXPECTED TO BENEFIT FROM HIGHER REVENUE, MODEST OPERATING. MARGIN IMPROVEMENT.CHARLES RIVER LABORATORIES - 2018 EARNINGS PER SHARE GUIDANCE INCLUDES GAIN OF $0.14 ON VENTURE CAPITAL INVESTMENTS.CHARLES RIVER LABORATORIES - 2018 EARNINGS PER SHARE GUIDANCE ALSO INCLUDES GAIN OF $0.14 FOR EXCESS TAX BENEFIT ASSOCIATED WITH STOCK COMPENSATION.CHARLES RIVER LABORATORIES SEES 2018 NON-GAAP EARNINGS PER SHARE INCLUDING MPI $5.67 - $5.82.  Full Article

Charles River Laboratories To Buy MPI Research For About $800 Mln
Tuesday, 13 Feb 2018 07:00am EST 

Feb 13 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES TO ACQUIRE MPI RESEARCH.CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL FOR APPROXIMATELY $800 MILLION.CHARLES RIVER LABORATORIES - DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP EPS BY APPROXIMATELY $0.25 IN 2018 AND APPROXIMATELY $0.60 IN 2019​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍FOR 2017, MPI IS EXPECTED TO GENERATE ANNUAL REVENUE OF APPROXIMATELY $240 MILLION​.CHARLES RIVER LABORATORIES INTERNATIONAL - ‍EXPECTS TO GENERATE OPERATIONAL SYNERGIES AS RESULT OF DEAL, WITH BENEFITS TOTALING $13 TO $16 MILLION BY END OF 2019​.CHARLES RIVER LABORATORIES - DEAL EXPECTED TO ADD $170 TO $190 MILLION TO CHARLES RIVER'S 2018 CONSOLIDATED REVENUE BASED ON ANTICIPATED TIMING OF CLOSE​.CHARLES RIVER LABORATORIES INTERNATIONAL - ‍ACQUISITION & ASSOCIATED FEES ARE EXPECTED TO BE FINANCED THROUGH AN EXPANSION OF CO'S CREDIT FACILITY & CASH​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍COMPANY IS EVALUATING FIXED-RATE DEBT FINANCING ALTERNATIVES WHICH COULD BE USED TO FINANCE ACQUISITION​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ACQUISITION IS EXPECTED TO ADD $260 TO $280 MILLION TO 2019 CONSOLIDATED REVENUE​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL,ASSOCIATED FEES EXPECTED TO BE FINANCED THROUGH EXPANSION OF CHARLES RIVER'S CREDIT FACILITY, CASH​.  Full Article

Charles River Laboratories Acquires KWS Biotest for GBP 15 Mln
Thursday, 11 Jan 2018 07:00am EST 

Jan 11 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES INTERNATIONAL INC - PURCHASE PRICE WAS APPROXIMATELY £15 MILLION IN CASH.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ TRANSACTION INCLUDES A POTENTIAL ADDITIONAL PAYMENT OF UP TO £3 MILLION BASED ON FUTURE PERFORMANCE​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.  Full Article

Charles River Laboratories Says New Tax Legislation Expected To Be Effectively Neutral To Co's GAAP, Non-GAAP EPS In 2018
Tuesday, 9 Jan 2018 08:19am EST 

Jan 9 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES SAYS NEW TAX LEGISLATION EXPECTED TO BE EFFECTIVELY NEUTRAL TO CO'S GAAP AND NON-GAAP EPS IN 2018 - SEC FILING.  Full Article

Charles River Laboratories reports Q3 non-GAAP EPS of $1.30
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Charles River Laboratories International Inc ::Updates 2017 guidance​.Announces third-quarter 2017 results from continuing operations.Q3 non-GAAP earnings per share $1.30.Q3 GAAP earnings per share $1.09.Q3 revenue $464.2 million versus I/B/E/S view $458.7 million.Q3 earnings per share view $1.22 -- Thomson Reuters I/B/E/S.Sees ‍2017 revenue growth, reported 9.75 percent - 10.5 percent​.Sees ‍2017 non-GAAP EPS estimate $5.08 - $5.18​.Sees ‍2017 GAAP EPS estimate $3.95 - $4.05​.FY2017 earnings per share view $5.10, revenue view $1.85 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River announces expansion of in vitro oncology services
Thursday, 26 Oct 2017 08:00am EDT 

Oct 26 (Reuters) - Charles River Laboratories International Inc :Charles River announces expansion of in vitro oncology services.Charles River Laboratories International Inc says partnership with InSphero AG, supplier of 3D solutions for in vitro drug discovery and development​.Charles River Laboratories International Inc - ‍through partnership, co will license its collection of patient-derived xenograft tumors to InSphero​.  Full Article

Charles River Laboratories posts Q2 adj. earnings $1.29/shr
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Charles River Laboratories International Inc :Charles River Laboratories announces second-quarter 2017 results from continuing operations.Q2 non-GAAP earnings per share $1.29.Q2 GAAP earnings per share $1.12.Q2 revenue $469.1 million versus I/B/E/S view $458 million.Q2 earnings per share view $1.22 -- Thomson Reuters I/B/E/S.Charles River Laboratories International Inc sees 2017 GAAP EPS estimate $4.18-$4.33.Charles River Laboratories International Inc sees 2017 non-GAAP EPS estimate $5.00- $5.15.Charles River Laboratories International Inc sees 2017 revenue growth, organic 7.0 pct - 8.5 pct.Q2 earnings per share view $1.22, revenue view $458.0 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $5.10, revenue view $1.83 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River Laboratories acquires Brains On-Line
Monday, 7 Aug 2017 07:30am EDT 

Aug 7 (Reuters) - Charles River Laboratories International Inc :Charles river laboratories acquires Brains On-Line.Charles River Laboratories International Inc - ‍purchase price was approximately EUR 18 million in cash​.Charles River Laboratories - ‍In addition to initial purchase price, deal includes potential additional payments of up to eur 6.7 million.Charles River Laboratories International Inc says ‍it has acquired Brains On-Line, a contract research organization​.  Full Article

Charles River Laboratories' Board increase size of board from nine to ten
Thursday, 6 Jul 2017 07:00am EDT 

July 6 (Reuters) - Charles River Laboratories International Inc :Charles River Laboratories International - on July 1, board of directors of co increased size of board from nine to ten - SEC filing.  Full Article

Charles River Laboratories reports Q1 non-GAAP earnings per share $1.29
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Charles River Laboratories International Inc : :Charles river laboratories announces first-quarter 2017 results from continuing operations.Q1 non-GAAP earnings per share $1.29.Q1 GAAP earnings per share $0.97.Q1 revenue $445.8 million versus I/B/E/S view $437.1 million.Q1 earnings per share view $1.14 -- Thomson Reuters I/B/E/S.Charles river laboratories international inc sees 2017 revenue growth, reported 7.5pct - 9.0pct.Charles River Laboratories International Inc sees 2017 non-gaap eps estimate $5.00 - $5.15.Sees 2017 GAAP eps estimate of $4.18-$4.33.Charles River Laboratories International Inc - company is maintaining its revenue guidance for 2017.FY2017 earnings per share view $5.06, revenue view $1.83 billion -- Thomson Reuters I/B/E/S.Sees 2017 revenue growth, organic of 7.0pct - 8.5pct.Sees 2017 non-GAAP EPS estimate of $5.00 - $5.15.  Full Article

Cancer center CEO leaves Merck board after disclosure scandal

NEW YORK The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from the boards of drugmaker Merck & Co Inc and lab services firm Charles River Laboratories International Inc on Tuesday, following media investigations about the U.S. center's ties to the pharmaceutical industry.